financetom
Business
financetom
/
Business
/
Psyence Group's RTO Target, GoldCoast Resource Corp., Granted Offshore Reconnaissance License for Gold Exploration on Ghana's Shallow Continental Shelf
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Psyence Group's RTO Target, GoldCoast Resource Corp., Granted Offshore Reconnaissance License for Gold Exploration on Ghana's Shallow Continental Shelf
Mar 11, 2026 1:50 AM

TORONTO, ON / ACCESS Newswire / January 27, 2026 / Psyence Group Inc. ( PSYGF ) ("Psyence ( PSYGF )" or the "Company") announces that its proposed reverse takeover target, GoldCoast Resource Corp. ("GoldCoast"), has been granted a series of ten contiguous offshore reconnaissance licenses by the Minerals Commission of Ghana (the "Reconnaissance Licenses") covering approximately 10,000 square kilometres along Ghana's western offshore continental shelf (the "License Area"). The Reconnaissance Licenses permit GoldCoast to conduct reconnaissance activities in accordance with Ghanaian mining regulations. The Reconnaissance Licenses have an initial term of 12 months and may be renewed in accordance with Ghanaian regulations.

The licenses represent the initial stage of Ghana's mineral tenure framework. Reconnaissance work is intended to identify areas that may warrant follow-up evaluation. Subject to exploration results and receipt of applicable regulatory approvals, portions of the License Area may be advanced to prospecting licenses and, subsequently, mining licenses. There can be no assurance that commercially viable mineralization will be identified or that any license will be advanced.

GoldCoast has advised Psyence ( PSYGF ) that it intends to undertake reconnaissance activities within the License Area in accordance with applicable Ghanaian laws and regulations.

As previously disclosed, Psyence ( PSYGF ) and GoldCoast continue to advance their proposed reverse takeover transaction, which remains subject to customary conditions, including completion of technical disclosure in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects, financial statement requirements, shareholder approval, and Canadian Securities Exchange acceptance.

ABOUT PSYENCE GROUP INC. ( PSYGF )

Psyence Group Inc. ( PSYGF ) is a life science biotechnology company focused on the development of nature-derived psychedelic products for mental health and wellness applications.

Psyence ( PSYGF ) is currently advancing a proposed reverse takeover transaction with GoldCoast Resource Corp., a private mineral exploration company focused on offshore gold exploration in Ghana. Upon completion of the transaction, the resulting issuer is expected to pursue the business of GoldCoast, subject to receipt of all required regulatory and shareholder approvals.

Psyence's ( PSYGF ) current operations are focused on research and development initiatives involving nature-derived psilocybin products. There can be no assurance that the proposed transaction will be completed as contemplated or at all.

Contact Information

Learn more at www.psyence.com.

Email: [email protected]

Media Inquiries: [email protected]

General Information: [email protected]

Phone: +1 416-477-1708

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility.

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements are based on expectations, estimates and projections as at the date of this news release and are subject to known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such statements.

Forward-looking statements in this news release include, but are not limited to, statements regarding the proposed reverse takeover transaction between Psyence ( PSYGF ) and GoldCoast, the anticipated timing and completion of the transaction, the satisfaction of regulatory, shareholder and Canadian Securities Exchange requirements, and the future business plans of the resulting issuer. Forward-looking statements are generally identified by words such as "may", "could", "would", "expect", "intend", "plan", "anticipate", "believe", or similar expressions.

There can be no assurance that the proposed transaction will be completed as currently contemplated or at all. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by applicable law, Psyence ( PSYGF ) undertakes no obligation to update or revise any forward-looking statements.

SOURCE: Psyence Group Inc. ( PSYGF )

View the original press release on ACCESS Newswire

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Eli Lilly Strikes $3.2 Billion Deal to Acquire Morphic
Eli Lilly Strikes $3.2 Billion Deal to Acquire Morphic
Jul 8, 2024
09:06 AM EDT, 07/08/2024 (MT Newswires) -- Eli Lilly ( LLY ) will buy biopharmaceutical company Morphic ( MORF ) for roughly $3.2 billion in a bid to expand its immunology portfolio with oral therapies targeting cell proteins for chronic diseases. The drugmaker will launch a tender offer to acquire all outstanding shares of Morphic ( MORF ) for $57...
Precision Drilling Extends Senior Credit Facility, Provides Update on 2024 Debt Repayment, Share Buyback
Precision Drilling Extends Senior Credit Facility, Provides Update on 2024 Debt Repayment, Share Buyback
Jul 8, 2024
09:06 AM EDT, 07/08/2024 (MT Newswires) -- Precision Drilling Corporation ( PDS ) has extended its senior credit facility and says it is on track to meet its 2024 debt reduction and share repurchase targets. The company extended its credit facility's maturity date to June 28, 2027, and revised the size to US$375 million (from US$447 million). The facility includes...
Merus Begins Phase 2 Trial of Colorectal Cancer Drug Candidate
Merus Begins Phase 2 Trial of Colorectal Cancer Drug Candidate
Jul 8, 2024
09:06 AM EDT, 07/08/2024 (MT Newswires) -- Merus (MRUS) said Monday it has dosed first patient in its phase 2 trial of petosemtamab combined with standard chemotherapy to treat second-line metastatic colorectal cancer. The open-label trial aims to evaluate the safety and preliminary antitumor activity of petosemtamab and chemotherapy in approximately 40 patients without prior EGFR inhibitor treatment. ...
Greenbrier's Fiscal Q3 Earnings Rise, Revenue Falls; Fiscal 2024 Revenue Guidance Updated
Greenbrier's Fiscal Q3 Earnings Rise, Revenue Falls; Fiscal 2024 Revenue Guidance Updated
Jul 8, 2024
09:05 AM EDT, 07/08/2024 (MT Newswires) -- Greenbrier (GBX) reported fiscal Q3 earnings Monday of $1.06 per diluted share, up from $0.64 per share a year earlier. Four analysts polled by Capital IQ expected $1.13. Revenue for the quarter ended May 31 was $820.2 million, down from $1.04 billion a year earlier. Four analysts surveyed by Capital IQ expected $920.9...
Copyright 2023-2026 - www.financetom.com All Rights Reserved